Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus PYOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus PYOPEN.
BICILLIN L-A vs PYOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
4 g intravenously every 4 hours.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic